{
  "ticker": "EMD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960363",
  "id": "02960363",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250620",
  "time": "0941",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250620/pdf/06ky2812phwtbl.pdf",
  "summary": "- **Key Event**: Chief Scientific Officer presenting at Psychedelic Science 2025, highlighting Emyria\u2019s reimbursement agreement with Medibank.  \n- **Strategic Highlight**: Medibank deal positions Emyria as a leader in funded mental health care models, addressing global reimbursement barriers.  \n- **Upcoming Catalyst**: Investor webinar planned for next week to detail the care model.  \n\n*No material trading or capital markets actions identified (operational/event update only).*",
  "usage": {
    "prompt_tokens": 1565,
    "completion_tokens": 99,
    "total_tokens": 1664,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-19T23:54:41.838168"
}